Disordered Metal Metabolism in a Large Autism Population

William J. Walsh, Anjum Usman, and Jeffrey Tarpey

Presented at the APA Annual Meeting, May, 2001 - New Orleans

Abstract

Objective: To investigate the incidence of metal metabolism disorders in an autistic-spectrum patient population.

Method: Chemical analyses of blood and urine samples from 503 patients diagnosed with autistic disorder (n=318), Asperger's disorder (n=23), or atypical autism (n=162) were evaluated.

Results: Of patients tested, 428 (85%) exhibited severely elevated Cu/Zn ratios in blood (average 1.78) compared to a population of healthy controls (average 1.15). Another 30 patients (6%) exhibited a pyrrole disorder associated with severe Zn deficiency. Of the remaining subjects (n=49), 45 reported undergoing aggressive Zn therapy at the time of sampling. A total of 499 of the 503 autism-spectrum patients exhibited evidence of a metal-metabolism disorder.

Conclusion: The absence of Cu and Zn homeostasis and severe Zn deficiency are suggestive of a metallothionein (MT) disorder. MT functions include neuronal development, detoxification of heavy metals, and immune response. Many classic symptoms of autism may be explained by a MT defect in infancy including G.I. tract problems, heightened sensitivity to toxic metals, and abnormal behaviors. These data suggest that an inborn error of MT functioning may be a fundamental cause of autism.

Summary

Recent research indicates that a metallothionein (MT) protein dysfunction may be a primary cause of autism. MT proteins are directly involved in development of brain neurons, detoxification of heavy metals, and immune response. Treatments to promote the induction and proper functioning of MT proteins are described.

William Walsh, Ph.D., is president of the non-profit Walsh Research Institute near Chicago (USA) and a key scientist driving the development of nutrient-based psychiatry. His book, Nutrient Power, which describes an evidence-based nutrient therapy system, is the result of his more than 30 years of research and clinical experience. Dr. Walsh has authored more than 200 scientific articles and reports, and has five patents. He directs an international physician-training program in advanced biochemical/nutrient therapies in Australia, Ireland, Norway and the United States used by doctors throughout the world.